Clinical trial · Interventional
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
A Study of the Effect of Anlotinib, Pemetrexed or the Combination As Maintenance Therapy for Patients With Non-Squamous Non-Small Cell Lung Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will compare maintenance therapy with anlotinib plus pemetrexed versus pemetrexed or anlotinib alone, in patients with Non-squamous Non-small cell lung cancer who have not progressed during first-line therapy with anlotinib + pemetrexed + carboplatin. The primary endpoint of the study is progression-free survival (PFS); the secondary endpoints are disease control rate (DCR), objective response rate (ORR) and overall survival (OS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-squamous Non-small-cell Lung Cancer | Lung Non-Squamous Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib | Drug | — | UNRESOLVED |
| Anlotinib + Pemetrexed | Drug | — | UNRESOLVED |
| Anlotinib + Pemetrexed+Carboplatin | Drug | — | UNRESOLVED |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- First-line Treatment
- interventionNames
- Drug: Anlotinib + Pemetrexed+Carboplatin
- type
- EXPERIMENTAL
- label
- Maintenance Treatment A
- interventionNames
- Drug: Pemetrexed
- type
- EXPERIMENTAL
- label
- Maintenance Treatment B
- interventionNames
- Drug: Anlotinib + Pemetrexed
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75, ECOG PS: 0\~1, estimated survival duration more than 3 months; 2. Subjects with histologically or cytologically confirmed locally advanced and/or advanced Non-squamous NSCLC; 3. Signed and dated informed consent; 4. adequate hematological, liver and renal function Exclusion Criteria: 1. prior chemotherapy or treatment with another systemic anti-cancer agent 2. malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS 3. evidence of tumor invading major blood vessels 4. current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes 5. history of haemoptysis \>/=grade 2 6. clinically significant cardiovascular disease
References
Publications (0)
Data not yet available